Overview

To Evaluate the Safety, Tolerability, PK, PK-PD Relation of KD101 in the Fed State in Obese or Overweight Subjects

Status:
Unknown status
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
To Evaluate the safety, tolerability and pharmacokinetic property after KD101 multiple oral dosing in the fed state in obese or overweight subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Kwang Dong Pharmaceutical co., ltd.